Anakinra for myocarditis in juvenile idiopathic arthritis

Texas Heart Institute Journal

Volumn 40, Issue 5, 2013, Pages 623-625

  Movva, Rajesh ^a   Brown, Suzanne B ^a   Lynn Morris, D ^a,b   Figueredo, Vincent M ^a,b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti inflammatory agents therapeutic use; Antirheumatic agents therapeutic use; Arthritis; Disease susceptibility; Heart drug effects; Interferon beta therapeutic use; Interleukin 1 receptor antagonist protein; Juvenile rheumatoid complications drug therapy; Left drug effects; Myocarditis diagnosis; Treatment outcome; Ventricular dysfunction

Indexed keywords

INOTROPIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE REPORT; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FLU LIKE SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; HYPOXIA; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LUNG EDEMA; MYOCARDITIS; ST SEGMENT DEPRESSION; T WAVE INVERSION; TACHYCARDIA; THORAX RADIOGRAPHY; YOUNG ADULT;

ANTI-INFLAMMATORY AGENTS/THERAPEUTIC USE; ANTIRHEUMATIC AGENTS/THERAPEUTIC USE; ARTHRITIS, JUVENILE RHEUMATOID/COMPLICATIONS/DRUG THERAPY; DISEASE SUSCEPTIBILITY; HEART/DRUG EFFECTS; INTERFERON-BETA/THERAPEUTIC USE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MYOCARDITIS/DIAGNOSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT/DRUG EFFECTS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MYOCARDITIS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; YOUNG ADULT;

EID: 84891709258     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107(22):2793-8.
2. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011;32(21):2616-25.
3. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al. Gamma-globulin treatment of acute myo carditis in the pediatric population. Circulation 1994;89(1): 252-7.
4. Bozkurt B, Villaneuva FS, Holubkov R, Tokarczyk T, Alvarez RJ Jr, MacGowan GA, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34(1):177-80.
5. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103(8):1044-7.
6. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109(13):1594-602.
7. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107(25):3133-40.
8. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, et al. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126(1):13-30.
9. Zeft AS, Menon SC, Miller D. Fatal myocarditis in a child with systemic onset juvenile idiopathic arthritis during treatment with an interleukin 1 receptor antagonist. Pediatr Rheumatol Online J 2012;10:8.
10. Ruiz PJ, Masliah E, Doherty TA, Quach A, Firestein GS. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 2007;66(3):422-3.
11. Merlin E, Berthomieu L, Dauphin C, Stephan JL. Cardiac tamponade in a child with systemic-onset juvenile idiopathic arthritis: dramatic improvement after interleukin-1 blockade by anakinra. Pediatr Cardiol 2011;32(6):862-3.
12. Raffeiner B, Botsios C, Dinarello C, Ometto F, Punzi L, Ramonda R. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 2011;78(1):100-1.
13. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008;117(20):2662-9.
14. Salloum FN, Chau V, Varma A, Hoke NN, Toldo S, Biondi-Zoccai GG, et al. Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter? Cardiovasc Drugs Ther 2009;23(2):129-35.
15. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008;117(20):2670-83.
16. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemiareperfusion injury associated with reduction in apoptosis. Circulation 2001;104(12 Suppl 1):I308-I3.
17. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010;105(10):1371-7. e1.
18. Berger CT, Recher M, Steiner U, Hauser TM. A patient's wish: anakinra in pregnancy [published erratum appears in Ann Rheum Dis 2010;69(1):28]. Ann Rheum Dis 2009;68 (11):1794-5.
19. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol 2011;29(6):1021-3.